SlideShare a Scribd company logo
PRESENTED BY
Heena Parveen,
M.Pharmacy(Pharmacology),
CP&PT.
Contents
• Definiton
• Types of Schizophrenia
• Epidemiology
• Symptoms
• Etiology
• Patho-physiology
• Diagnosis
• Drug Therapy
Schizophrenia is a chronic
heterogeneous syndrome of disorganized and
bizarre thoughts, delusions, hallucinations,
inappropriate affect, cognitive deficits, and
impaired psychosocial functioning
• It is a psychotic disorder marked by
severely impaired thinking, emotions and
behaviours. Schizophrenic patients are
unable to filter sensory stimuli and may
have enhanced perception of sounds,
colours and other features of their
environment.
• Most schizophrenics, if untreated can
gradually withdraw themselves from the
interactions with other people and lose their
ability to take care of personnel needs
TYPES OF SCHIZOPHRENIA
CATATONIC
Motor symptoms are most notable. The
patient may either demonstrate rigid
immobility or excessive purposeless
movement. The patient may be silent
and withdrawn or may become loud and
shout.
Bizarre voluntary movements such as
posturing may also occur.
The patient may fluctuate between the
two extremes.
DISORGANISED
The patient tends to have
disorganized speech and
behavior with a fl at affect.
Hallucinations
and delusions are not well
formed and fragmented. The
patient may also have bizarre
mannerisms and grimacing.
PARANOID
The most common type of
schizophrenia. Patients are
usually preoccupied with
paranoid delusions or auditory
hallucinations. Cognitive
function is usually preserved; if
thought disorder is present, it
does not prevent description of
delusions or hallucinations.
RESIDUAL
The patient does not have
acute psychosis, but some
symptoms of
schizophrenia remain.
Largely negative
symptoms are seen, such
as flat affect, social
withdrawal, and loose
associations. Prominent
delusions or hallucinations
are not present.
UNDIFFERENTIATED
The patient meets the criteria for a diagnosis
of schizophrenia but does not meet the
criteria for a specific type, or the patient may
meet the criteria for multiple types of
schizophrenia. No one type appears to be
dominant.
EPIDEMIOLOGY
Lifetime prevalence of schizophrenia ranges from 0.6% to
1.9%, with an average of approximately 1%.
The worldwide prevalence of schizophrenia is remarkably
similar among all cultures.
Schizophrenia most commonly has its onset in late
adolescence or early adulthood and rarely occurs before
adolescence or after the age of 40 years.
The prevalence of schizophrenia is equal in males and
females.
SYMPTOMS OF
SCHIZOPHRENIA
POSITIVE SYMPTOMS
DELUSION
HALLUCINATION
COMBATIVENESS
INSOMNIA
NEGATIVE SYMPTOMS
Affective flattening
Alogia
Anhedonia
Amotivation
Apathy
Asocial behavior
DISORGANIZED SYMPTOMS
Disorganized speech
Thought disorder
Disorganized behavior
Poor attention
ETIOLOGY
• No one knows the exact causes of
Schizophrenia, but multiple possible
factors have been discovered.
• These factors include:
1. Genetics
2. Brain chemical imbalance
3. Environmental factors
4. Family history
PATHOPHYSIOLOGY
Genetic Theory:
• A strong genetic link exists for the development of
schizophrenia.
 Occurs in 1% of general population, however this increases to
10% if a 1st degree relative has a history of schizophrenia.
 Risk of developing schizophrenia further increases to 40%
when both parents have a history of schizophrenia.
 Studies are going to locate specific genes to the development
of schizophrenia.
Dopamine Theory:
• The dopamine hyperactivity in the brain is responsible for
psychotic symptoms present in schizophrenia.
 While dopamine hyperactivity is present in mesolimbic
pathway, other areas of the brain such as the prefrontal, frontal
and temporal cortices have decrease activity during acute
psychosis.
 Other neurotransmitters thought to be involved in
schizophrenia include 5-HT, glutamate.
 The role of glutamate is also being evaluated because one of its
major functions is to regulate dopamine activity. Glutamate
deficiency has been found to cause similar effects to that of
dopamine hyperactivity.
Neuro-developmental Theory:
• Schizophrenia occurs as a result of an in
Utero disturbance during pregnancy.
Potential causes of this disturbance include upper
respiratory infection, obstetric complication and
neonatal hypoxia.
Psychosocial Theories:
• These theories propose that situation such
as stress, poor interpersonal skills,
conflicting family, communication and
various socio-economic influences are
linked to development of schizophrenia.
Neurotransmitter Abnormalities
• Abnormalities in the dopaminergic system
– Hypo-dopaminergic activity in the mesocortical
system, leading to negative symptoms
– Hyper-dopaminergic activity in the mesolimbic
system, leading to positive symptoms
Schizophrenia  pathophysiology
• The Diagnostic and Statistical Manual of Mental Disorders,
specifies the following criteria for the diagnosis of
schizophrenia:
✓ Persistent dysfunction lasting longer than 6 months
✓ Two or more symptoms (present for at least 1 month),
including hallucinations, delusions, disorganized speech,
grossly disorganized or catatonic behavior, and negative
symptoms
✓ Significantly impaired functioning (work, interpersonal, or
self-care)
DIAGNOSIS
• Schizophrenic patients appear to have small brains with large
ventricular volumes, indicating a relative deficit of neurons.
• Structural and functional brain imaging studies have strongly
suggested that regions of the medial temporal lobe (e.g.,
hippocampus) have diminished numbers of neurons and also
have demonstrated the inability of individuals with
schizophrenia to activate the frontal cortex and successfully
execute tasks that require frontal cortical function.
IMAGING
Ventricular enlargement and cortical atrophy, as seen on CT scan, have
been correlated with chronic course, severe cognitive impairment, and non
responsiveness to neuroleptic medications.
Decreased frontal lobe activity seen on PET scan has been associated with
negative symptoms.
Schizophrenia  pathophysiology
TREATMENT
GOALS AND OBJECTIVES:
There is currently no known cure for schizophrenia.
 Treatment options include psychotherapy as well as
pharmacotherapy.
The goals and objectives of treatment are as follows:
A. Minimize symptoms of schizophrenia
B. Improve quality of life and social/occupational functioning
C. Prevent relapse and hospitalization
D. Minimize adverse effects of medications
E. Prevent suicide attempts or self-harm
NON-PHARMACOLOGICAL
TREATMENT
• Psychotherapy
• Family therapy
PHARMACOLOGICAL
TREATMENT
• Antipsychotic medications:
Two generation of antipsychotic medications are available for
treatment:
1. First generation or typical antipsychotics
2. Second Generation or Atypical Antipsychotics:
First generation or typical antipsychotics:
Chlorpromazine
Trifluperazine
Thioridazine
Perphanazine
Fluphenazine
Haloperidol
Loxapine
• Mechanism of Action:
The antipsychotic effect of these medications
is primarily mediated through the blockade of
dopamine type 2 (D2 receptors).
Adverse effects:
Sedation,
anticholinergic effects,
EPS
hyperprolactemia,
moderate weight gain
Photosensitivity
Second Generation or Atypical
Antipsychotics
Clonazapine
Risperidone
Olanzapine
Quetipine
Ziprasidone
• Mechanism of action:
Atypical antipsychotics are dopamine
antagonists but also block 5-HT2A-receptors
Adverse effects:
Sedation, anticholinergic effects
(Clonazapine, Olanzapine), EPS,
DM, hyperprolactemia
(Risperidone), hypercholestremia
References
1. Text book of Clinical Pharmacy and
Therapeutics
2. Text book of Pharmacology by RANG and
DALE’S.
3. Essentials of Medical Pharmacology by
K.D.Tripathi.
Schizophrenia  pathophysiology

More Related Content

PDF
Pathophysiology of Schizophrenia
PPTX
PPTX
SCHIZOPHRENIA.pptx
PPTX
Schizophrenia
PPTX
Pathophysiology of depression
PDF
Mania,depression and Schizophrenia
PPTX
Affective Disorders
PPTX
Pharmacotherapy of Schizophrenia
Pathophysiology of Schizophrenia
SCHIZOPHRENIA.pptx
Schizophrenia
Pathophysiology of depression
Mania,depression and Schizophrenia
Affective Disorders
Pharmacotherapy of Schizophrenia

What's hot (20)

PPTX
Antipsychotics
PPTX
Antipsychotic drugs
PPTX
Antidepressants Pharmacology
PPTX
Antianxiety drugs
PPT
Pharmacology - Parkinsonism
PPTX
Antipsychotic drugs
PPTX
Antidepressants -pharmacology
PPTX
ANTIDEPRESSANTS
PPTX
chlorpromazine(Antipsychotic Drug)
PPTX
Mood Stabilisers (Antimanic drugs)
PPTX
Psychotropic drugs
PPTX
Anticonvulsant drugs
KEY
Clozapine
PPT
Anxiolytic drugs
PPTX
Depression
PPTX
Schizophrenia
PPTX
Antidepressant drugs
PPTX
Antimanic drugs and its pharmacology
PPTX
ANTIDEPRESSANTS
PPTX
Antidepressants
Antipsychotics
Antipsychotic drugs
Antidepressants Pharmacology
Antianxiety drugs
Pharmacology - Parkinsonism
Antipsychotic drugs
Antidepressants -pharmacology
ANTIDEPRESSANTS
chlorpromazine(Antipsychotic Drug)
Mood Stabilisers (Antimanic drugs)
Psychotropic drugs
Anticonvulsant drugs
Clozapine
Anxiolytic drugs
Depression
Schizophrenia
Antidepressant drugs
Antimanic drugs and its pharmacology
ANTIDEPRESSANTS
Antidepressants
Ad

Similar to Schizophrenia pathophysiology (20)

PPTX
Schizophrenia
PPTX
Schizophrenia Disoder power point ...........
PPTX
Schizophrenia
PPTX
schizophrenia-170411105432134321114.pptx
PPTX
schizophrenia-170411105434 (1).pptxprphe
PPTX
Schizophrenia- a brief view
PPTX
Schizophrenia
PDF
SCHIZOPHRENIA Final RK, Bobby and Trevor.pdf
PPTX
Schizophrenia
PDF
Scezophernia full ppt information presentation
PDF
Presentation4.pdf scezophrenia full information
PPTX
An overview of DRUG USED IN SCHIZOPHRENIA.pptx
PPTX
SCHIZOPHRENIA
PPTX
Schizophrenia and other Psychoticdisorder.pptx
PPTX
SCHIZOPHRENIA class Final RK and Bobby.pptx
PPTX
SCHIZOPHRENIA.pptx
PPTX
schizophrenia and management slideshare.pptx
PPT
Schizophrenia Disorder
PPTX
Schizophrenia - Renu.s
PPTX
Schizophrenia
Schizophrenia
Schizophrenia Disoder power point ...........
Schizophrenia
schizophrenia-170411105432134321114.pptx
schizophrenia-170411105434 (1).pptxprphe
Schizophrenia- a brief view
Schizophrenia
SCHIZOPHRENIA Final RK, Bobby and Trevor.pdf
Schizophrenia
Scezophernia full ppt information presentation
Presentation4.pdf scezophrenia full information
An overview of DRUG USED IN SCHIZOPHRENIA.pptx
SCHIZOPHRENIA
Schizophrenia and other Psychoticdisorder.pptx
SCHIZOPHRENIA class Final RK and Bobby.pptx
SCHIZOPHRENIA.pptx
schizophrenia and management slideshare.pptx
Schizophrenia Disorder
Schizophrenia - Renu.s
Schizophrenia
Ad

More from Heena Parveen (20)

PPTX
NSAID'S --ASPIRIN
PPTX
NSAID'S
PPTX
Bioassay of Digitalis, d-tubocurarine , Oxytocin
PPTX
Bioassay of insulin & Bioassay of Vasopressin
PPTX
Bioassay ,its types for theory & practical
PPTX
Neuromuscular blockers &; skeletal muscle relaxants
PPTX
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICS
PPTX
Parasympathomimetcs ; Cholinomimetics , Parasympathomimetics ;Anti-Choliester...
PPTX
NEUROTRANSMITTERS & RECEPTORS IN ANS
PPTX
NEUROHUMORAL TRANSMISSION
PPTX
ORGANSATION & FUNCTIONS OF ANS
DOCX
Dose response relationship
DOCX
Dose response relationship
PPTX
FACTORS MODIFYING DRUG ACTION
DOCX
Typhoid fever
PPTX
Types of receptor signal transduction pathways
PPTX
Drug discovery & clinical evaluation of new drugs
PPTX
Transfer pricing
PPTX
Pharmacokinetics absorption,distribution,metabolism,excretion
PPTX
Receptors types
NSAID'S --ASPIRIN
NSAID'S
Bioassay of Digitalis, d-tubocurarine , Oxytocin
Bioassay of insulin & Bioassay of Vasopressin
Bioassay ,its types for theory & practical
Neuromuscular blockers &; skeletal muscle relaxants
Sympathomimetics / ADRENERGICS / SYMPATHOLYTICS
Parasympathomimetcs ; Cholinomimetics , Parasympathomimetics ;Anti-Choliester...
NEUROTRANSMITTERS & RECEPTORS IN ANS
NEUROHUMORAL TRANSMISSION
ORGANSATION & FUNCTIONS OF ANS
Dose response relationship
Dose response relationship
FACTORS MODIFYING DRUG ACTION
Typhoid fever
Types of receptor signal transduction pathways
Drug discovery & clinical evaluation of new drugs
Transfer pricing
Pharmacokinetics absorption,distribution,metabolism,excretion
Receptors types

Recently uploaded (20)

PPTX
CME 2 Acute Chest Pain preentation for education
PDF
CT Anatomy for Radiotherapy.pdf eryuioooop
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PPT
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
PDF
Human Health And Disease hggyutgghg .pdf
PPTX
Neuropathic pain.ppt treatment managment
PDF
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
PPTX
Respiratory drugs, drugs acting on the respi system
PPT
Breast Cancer management for medicsl student.ppt
PPTX
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
PDF
Deadly Stampede at Yaounde’s Olembe Stadium Forensic.pdf
PPT
CHAPTER FIVE. '' Association in epidemiological studies and potential errors
PPTX
Imaging of parasitic D. Case Discussions.pptx
PPT
MENTAL HEALTH - NOTES.ppt for nursing students
PPTX
Slider: TOC sampling methods for cleaning validation
PPTX
Uterus anatomy embryology, and clinical aspects
PPT
OPIOID ANALGESICS AND THEIR IMPLICATIONS
PPT
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPTX
Gastroschisis- Clinical Overview 18112311
CME 2 Acute Chest Pain preentation for education
CT Anatomy for Radiotherapy.pdf eryuioooop
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
1b - INTRODUCTION TO EPIDEMIOLOGY (comm med).ppt
Human Health And Disease hggyutgghg .pdf
Neuropathic pain.ppt treatment managment
Intl J Gynecology Obste - 2021 - Melamed - FIGO International Federation o...
Respiratory drugs, drugs acting on the respi system
Breast Cancer management for medicsl student.ppt
NEET PG 2025 Pharmacology Recall | Real Exam Questions from 3rd August with D...
Deadly Stampede at Yaounde’s Olembe Stadium Forensic.pdf
CHAPTER FIVE. '' Association in epidemiological studies and potential errors
Imaging of parasitic D. Case Discussions.pptx
MENTAL HEALTH - NOTES.ppt for nursing students
Slider: TOC sampling methods for cleaning validation
Uterus anatomy embryology, and clinical aspects
OPIOID ANALGESICS AND THEIR IMPLICATIONS
genitourinary-cancers_1.ppt Nursing care of clients with GU cancer
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
Gastroschisis- Clinical Overview 18112311

Schizophrenia pathophysiology

  • 2. Contents • Definiton • Types of Schizophrenia • Epidemiology • Symptoms • Etiology • Patho-physiology • Diagnosis • Drug Therapy
  • 3. Schizophrenia is a chronic heterogeneous syndrome of disorganized and bizarre thoughts, delusions, hallucinations, inappropriate affect, cognitive deficits, and impaired psychosocial functioning
  • 4. • It is a psychotic disorder marked by severely impaired thinking, emotions and behaviours. Schizophrenic patients are unable to filter sensory stimuli and may have enhanced perception of sounds, colours and other features of their environment. • Most schizophrenics, if untreated can gradually withdraw themselves from the interactions with other people and lose their ability to take care of personnel needs
  • 5. TYPES OF SCHIZOPHRENIA CATATONIC Motor symptoms are most notable. The patient may either demonstrate rigid immobility or excessive purposeless movement. The patient may be silent and withdrawn or may become loud and shout. Bizarre voluntary movements such as posturing may also occur. The patient may fluctuate between the two extremes. DISORGANISED The patient tends to have disorganized speech and behavior with a fl at affect. Hallucinations and delusions are not well formed and fragmented. The patient may also have bizarre mannerisms and grimacing.
  • 6. PARANOID The most common type of schizophrenia. Patients are usually preoccupied with paranoid delusions or auditory hallucinations. Cognitive function is usually preserved; if thought disorder is present, it does not prevent description of delusions or hallucinations. RESIDUAL The patient does not have acute psychosis, but some symptoms of schizophrenia remain. Largely negative symptoms are seen, such as flat affect, social withdrawal, and loose associations. Prominent delusions or hallucinations are not present.
  • 7. UNDIFFERENTIATED The patient meets the criteria for a diagnosis of schizophrenia but does not meet the criteria for a specific type, or the patient may meet the criteria for multiple types of schizophrenia. No one type appears to be dominant.
  • 8. EPIDEMIOLOGY Lifetime prevalence of schizophrenia ranges from 0.6% to 1.9%, with an average of approximately 1%. The worldwide prevalence of schizophrenia is remarkably similar among all cultures. Schizophrenia most commonly has its onset in late adolescence or early adulthood and rarely occurs before adolescence or after the age of 40 years. The prevalence of schizophrenia is equal in males and females.
  • 9. SYMPTOMS OF SCHIZOPHRENIA POSITIVE SYMPTOMS DELUSION HALLUCINATION COMBATIVENESS INSOMNIA NEGATIVE SYMPTOMS Affective flattening Alogia Anhedonia Amotivation Apathy Asocial behavior DISORGANIZED SYMPTOMS Disorganized speech Thought disorder Disorganized behavior Poor attention
  • 10. ETIOLOGY • No one knows the exact causes of Schizophrenia, but multiple possible factors have been discovered. • These factors include: 1. Genetics 2. Brain chemical imbalance 3. Environmental factors 4. Family history
  • 11. PATHOPHYSIOLOGY Genetic Theory: • A strong genetic link exists for the development of schizophrenia.  Occurs in 1% of general population, however this increases to 10% if a 1st degree relative has a history of schizophrenia.  Risk of developing schizophrenia further increases to 40% when both parents have a history of schizophrenia.  Studies are going to locate specific genes to the development of schizophrenia.
  • 12. Dopamine Theory: • The dopamine hyperactivity in the brain is responsible for psychotic symptoms present in schizophrenia.  While dopamine hyperactivity is present in mesolimbic pathway, other areas of the brain such as the prefrontal, frontal and temporal cortices have decrease activity during acute psychosis.  Other neurotransmitters thought to be involved in schizophrenia include 5-HT, glutamate.  The role of glutamate is also being evaluated because one of its major functions is to regulate dopamine activity. Glutamate deficiency has been found to cause similar effects to that of dopamine hyperactivity.
  • 13. Neuro-developmental Theory: • Schizophrenia occurs as a result of an in Utero disturbance during pregnancy. Potential causes of this disturbance include upper respiratory infection, obstetric complication and neonatal hypoxia.
  • 14. Psychosocial Theories: • These theories propose that situation such as stress, poor interpersonal skills, conflicting family, communication and various socio-economic influences are linked to development of schizophrenia.
  • 15. Neurotransmitter Abnormalities • Abnormalities in the dopaminergic system – Hypo-dopaminergic activity in the mesocortical system, leading to negative symptoms – Hyper-dopaminergic activity in the mesolimbic system, leading to positive symptoms
  • 17. • The Diagnostic and Statistical Manual of Mental Disorders, specifies the following criteria for the diagnosis of schizophrenia: ✓ Persistent dysfunction lasting longer than 6 months ✓ Two or more symptoms (present for at least 1 month), including hallucinations, delusions, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms ✓ Significantly impaired functioning (work, interpersonal, or self-care) DIAGNOSIS
  • 18. • Schizophrenic patients appear to have small brains with large ventricular volumes, indicating a relative deficit of neurons. • Structural and functional brain imaging studies have strongly suggested that regions of the medial temporal lobe (e.g., hippocampus) have diminished numbers of neurons and also have demonstrated the inability of individuals with schizophrenia to activate the frontal cortex and successfully execute tasks that require frontal cortical function. IMAGING Ventricular enlargement and cortical atrophy, as seen on CT scan, have been correlated with chronic course, severe cognitive impairment, and non responsiveness to neuroleptic medications. Decreased frontal lobe activity seen on PET scan has been associated with negative symptoms.
  • 20. TREATMENT GOALS AND OBJECTIVES: There is currently no known cure for schizophrenia.  Treatment options include psychotherapy as well as pharmacotherapy. The goals and objectives of treatment are as follows: A. Minimize symptoms of schizophrenia B. Improve quality of life and social/occupational functioning C. Prevent relapse and hospitalization D. Minimize adverse effects of medications E. Prevent suicide attempts or self-harm
  • 22. PHARMACOLOGICAL TREATMENT • Antipsychotic medications: Two generation of antipsychotic medications are available for treatment: 1. First generation or typical antipsychotics 2. Second Generation or Atypical Antipsychotics:
  • 23. First generation or typical antipsychotics: Chlorpromazine Trifluperazine Thioridazine Perphanazine Fluphenazine Haloperidol Loxapine
  • 24. • Mechanism of Action: The antipsychotic effect of these medications is primarily mediated through the blockade of dopamine type 2 (D2 receptors). Adverse effects: Sedation, anticholinergic effects, EPS hyperprolactemia, moderate weight gain Photosensitivity
  • 25. Second Generation or Atypical Antipsychotics Clonazapine Risperidone Olanzapine Quetipine Ziprasidone
  • 26. • Mechanism of action: Atypical antipsychotics are dopamine antagonists but also block 5-HT2A-receptors Adverse effects: Sedation, anticholinergic effects (Clonazapine, Olanzapine), EPS, DM, hyperprolactemia (Risperidone), hypercholestremia
  • 27. References 1. Text book of Clinical Pharmacy and Therapeutics 2. Text book of Pharmacology by RANG and DALE’S. 3. Essentials of Medical Pharmacology by K.D.Tripathi.